Search results for "controlled"

showing 10 items of 2729 documents

Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placeb…

2016

Evidence supporting the use of second generation antipsychotics (SGAs) in the treatment of acute depression with mixed features (MFs) associated with bipolar disorder (BD) is scarce and equivocal. Therefore, we conducted a systematic review and preliminary meta-analysis investigating SGAs in the treatment of acute BD depression with MFs. Two authors independently searched major electronic databases from 1990 until September 2015 for randomized (placebo-) controlled trials (RCTs) or open-label clinical trials investigating the efficacy of SGAs in the treatment of acute bipolar depression with MFs. A random-effect meta-analysis calculating the standardized mean difference (SMD) between SGA an…

Bipolar DisorderManic-depressive illness--Treatmentmeta-analysilcsh:ChemistryClinical trials0302 clinical medicineManic-depressive illnessAsenapineAntipsychotic drugslcsh:QH301-705.5Spectroscopydiagnostic and statistical manual for mental disorders fifth edition (DSM-5)PsychiatryDepressionBrief ReportGeneral MedicineComputer Science ApplicationsTreatment OutcomeMeta-analysismixed featureHumanmedicine.drugAntipsychotic Agentsmedicine.medical_specialtyAcute bipolar depression; Diagnostic and statistical manual for mental disorders fifth edition (DSM-5); Meta-analysis; Mixed features; Second generation antipsychotic (SGA); Systematic-review; Physical and Theoretical Chemistry; Organic Chemistry; Spectroscopy; Inorganic Chemistry; Catalysis; Molecular BiologyYoung Mania Rating ScalePlaceboCatalysisInorganic Chemistry03 medical and health sciencessystematic-reviewInternal medicinemedicineHumansZiprasidoneBipolar disorderPhysical and Theoretical ChemistryPsychiatryMolecular BiologyLurasidonemixed featuresbusiness.industryOrganic Chemistrysecond generation antipsychotic (SGA)acute bipolar depressionmedicine.disease030227 psychiatrymeta-analysisAntipsychotic Agentlcsh:Biology (General)lcsh:QD1-999QuetiapineControlled Clinical Trials as Topicbusiness030217 neurology & neurosurgeryInternational Journal of Molecular Sciences
researchProduct

Hybrid ferrocene ligands (P, N) : synthesis, coordination to metals and applications in arylation coupling catalysis

2017

The research theme developed during this thesis concerns the development of new hybrid ferrocene hybrid (P, N) ligands with controlled conformation, robust and stable to air. These hybrid tetradent ligands comprise two types of coordinating functions with distinct steric and electronic properties. Their coordination chemistry with metals such as gold or palladium has been studied and some isolated Au (I) complexes have been used in the arylation coupling catalysis of aryl iodides.

Bis(aminométhyl)-ferrocèneN) à conformation contrôléeNitrogenCouplage C-CRMN 15NBis (aminomethyl)-ferroceneAzoteFunctionalization of ferrocenePhosphorusOrHybrid ligandsHybrid ligands (PFonctionnalisation de ferrocène[CHIM.OTHE] Chemical Sciences/OtherLigands hybridesPhosphoreLigands hybrides-(PGoldFerrocene15N NMRLigands multidentes[CHIM.OTHE]Chemical Sciences/OtherN) with controlled conformationPalladiumC-C cross Coupling
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

Eating Competence of Elderly Spanish Adults Is Associated with a Healthy Diet and a Favorable Cardiovascular Disease Risk Profile

2010

Eating competence (EC), a bio-psychosocial model for intrapersonal approaches to eating and food-related behaviors, is associated with less weight dissatisfaction, lower BMI, and increased HDL-cholesterol in small U.S. studies, but its relationship to nutrient quality and overall cardiovascular risk have not been examined. Prevención con Dieta Mediterránea (PREDIMED) is a 5-y controlled clinical trial evaluating Mediterranean diet efficacy on the primary prevention of cardiovascular diseases (CVD) in Spain. In a cross-sectional study, 638 PREDIMED participants (62% women, mean age 67 y) well phenotyped for cardiovascular risk factors were assessed for food intake and EC using validated ques…

Blood GlucoseMaleAgingmedicine.medical_specialtyMediterranean dietCross-sectional studyMedicine (miscellaneous)Blood sugarBody Mass Indexlaw.inventionEatingRandomized controlled trialRisk FactorslawMediterranean dietSurveys and QuestionnairesInternal medicineHumansMedicineSingle-Blind MethodMetabolic systemAgedNutrition and Dieteticsbusiness.industryPREDIMED studymedicine.diseaseObesityDietClinical trialCholesterolCross-Sectional StudiesEndocrinologyBlood chemistryCardiovascular DiseasesSpainFemaleRandomized trialbusinessBody mass indexThe Journal of Nutrition
researchProduct

Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized c…

2016

Background & aims: Inositols are thought to be mediators of the insulin signalling pathway. We assessed the effects of inositols on glycaemic control in fasting and postprandial states and evaluated lipoprotein profile and LDL particle size in healthy population. Methods: A 12-week double-blind clinical trial was performed with forty healthy subjects administered either an inositol-enriched beverage (IEB) -containing 2.23 g of inositols in 250 ml- or a sucrose-sweetened beverage (SB) twice a day. Anthropometric measurements, fasting glucose levels, insulin and HOMA-IR index, lipoprotein profile and postprandial glucose concentrations (measured using the continuous glucose monitoring system …

Blood GlucoseMaleApolipoprotein Bmedicine.medical_treatment030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicinelaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawContinuous glucose monitoring systemHealthy subjects030212 general & internal medicineHypolipidemic AgentsNutrition and DieteticsbiologyArea under the curveFabaceaePostprandial PeriodPostprandialLDL particle sizeSeedsFemaleInositolsAdultmedicine.medical_specialtyCarob pod extractMonitoring AmbulatoryHyperlipidemias03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansHypoglycemic AgentsParticle SizePinitolPlant Extractsbusiness.industryPinitolInsulinMetabolismEndocrinologyLipoproteins IDLchemistrySpainFruitHyperglycemiaDietary Supplementsbiology.proteinInsulin ResistancebusinessInositolLipoproteinClinical Nutrition
researchProduct

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular …

2012

Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…

Blood GlucoseMaleBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAEndocrinology Diabetes and Metabolismpioglitazone sulfonylurea type 2 diabetes metformin cardiovascular eventsMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - EndocrinologiaBody Mass Indexlaw.inventionRandomized controlled trialRisk FactorslawSurveys and QuestionnairesCardiovascular DiseasepioglitazonepiogllitazoneStrokeDiabetes Therapy PioglitazoneNutrition and DieteticsDiabetesThiazolidinedionecardiovascular events; pioglitazone; Type 2 Diabetes Mellitus; sulphonylureasType 2 diabetesMiddle AgedMetforminSulfonylurea CompoundTreatment OutcomeTolerabilitysulphonylureasCardiovascular DiseasesDrug Therapy CombinationFemaletype 2 diabetesCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyEndpoint Determinationsulfonylureacardiovascualr eventSudden deathFollow-Up Studiecardiovascular eventsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentssulfonylureasinterventio trialtype 2 diabetes; cardiovascular events; pioglitazone; sulfonylureas; randomized controlled trialAgedHypoglycemic AgentQuestionnairebusiness.industryRisk Factormedicine.diseaseSurgeryType 2 Diabetes MellitusSulfonylurea CompoundsDiabetes Mellitus Type 2randomized controlled trialQuality of LifeThiazolidinedionesTherapybusinessmetforminPioglitazoneFollow-Up Studies
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

A 2 year physical activity and dietary intervention attenuates the increase in insulin resistance in a general population of children: the PANIC stud…

2020

Abstract Aims/hypothesis We studied for the first time the long-term effects of a combined physical activity and dietary intervention on insulin resistance and fasting plasma glucose in a general population of predominantly normal-weight children. Methods We carried out a 2 year non-randomised controlled trial in a population sample of 504 children aged 6–9 years at baseline. The children were allocated to a combined physical activity and dietary intervention group (306 children at baseline, 261 children at 2-year follow-up) or a control group (198 children, 177 children) without blinding. We measured fasting insulin and fasting glucose, calculated HOMA-IR, assessed physical activity and se…

Blood GlucoseMaleEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhysiologyphysical activitylean body massruokavaliotBody fat percentageHOMA-IRlaw.inventionBody Mass Indexglukoosi0302 clinical medicineRandomized controlled triallawInsulinBody Size030212 general & internal medicineglucoseChildChildreninterventioneducation.field_of_studyBody movementinterventiotutkimusFastingSedentary timebody fatLean body massBody fatBody CompositionFemalefyysinen aktiivisuusinsulinPopulationsedentary time030209 endocrinology & metabolismlapset (ikäryhmät)InterventioninsuliiniArticle03 medical and health sciencesInsulin resistancechildrenHeart rateInternal MedicinemedicineHumanseducationExercisekehonkoostumusbusiness.industryPhysical activityInsulinmedicine.diseaseDietGlucoseLean body massInsulin Resistancebusinessdiet
researchProduct

Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the …

2019

OBJECTIVE: To examine the effects of two Mediterranean eating plans (Med-EatPlans) versus a low-fat eating plan on the need for glucose-lowering medications. RESEARCH DESIGN AND METHODS: From the Prevención con Dieta Mediterránea (PREDIMED) trial, we selected 3,230 participants with type 2 diabetes at baseline. These participants were randomly assigned to one of three eating plans: Med-EatPlan supplemented with extra-virgin olive oil (EVOO), Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan (control). In a subgroup (15%), the allocation was done in small clusters instead of using individual randomization, and the clustering effect was taken into account in the statistical a…

Blood GlucoseMaleResearch designmedicine.medical_specialtyRandomizationEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismSubgroup analysisType 2 diabetesDiet Mediterraneanlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic Agents030212 general & internal medicinePropensity ScoreDiet Fat-RestrictedOlive OilDieta -- Mediterrània Regió de laAgedProportional Hazards ModelsAdvanced and Specialized NursingDiabetisbusiness.industryHazard ratioClinical Care/Education/Nutrition/Psychosocial ResearchMiddle Agedmedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2Multivariate AnalysisPropensity score matchingFemale0405business
researchProduct

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial

2021

Abstract Background Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiovascular risk validated by some studies include arterial stiffness and endothelial function indexes. To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on endothelial and arterial stiffness indexes as surrogate markers of vascular damage. Aims We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatmen…

Blood GlucoseMalelcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaTime FactorsEndocrinology Diabetes and MetabolismGlucagon-Like PeptidesBlood PressureType 2 diabetesGastroenterologylaw.inventionRandomized controlled triallawPulse wave velocityOriginal InvestigationDiabetesMiddle AgedLipidsVasodilationTreatment OutcomeItalyDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyRecombinant Fusion ProteinsIncretinsGlucagon-Like Peptide-1 ReceptorVascular StiffnessDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsDulaglutideAngiologyAgedVascular healthGlycated Hemoglobinbusiness.industrymedicine.diseasedulaglutide diabetes arterial stiffnessImmunoglobulin Fc FragmentsBlood pressureDiabetes Mellitus Type 2lcsh:RC666-701Arterial stiffnessDulaglutidebusinessBiomarkersCardiovascular Diabetology
researchProduct